[Antigenic properties of concentrated antirabies vaccine in accelerated immunization schedules]. 1980

R S Mad'iarova, and A V Dulina, and D V Krutilina, and R G Latypova, and V M Morogova

The study of purified rabies vaccine (tissue culture origin), concentrated 100 fold, in animal experiments has shown that the preparation, if introduced intramuscularly in 2 or 3 injections, has high antigenic activity. The intramuscular injections of the vaccine at an interval of 21 days or at intervals of 21 and 30 days after the first injection has proved to be the optimum immunization schedule ensuring a sufficiently high accumulation of virus-neutralizing antibodies by days 30--45. To achieve higher antibody titers, the vaccine may be introduced intradermally after 2 indispensable intramuscular injections of the preparation.

UI MeSH Term Description Entries
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D007271 Injections, Intradermal The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer. Intradermal Injections,Injection, Intradermal,Intradermal Injection
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D011818 Rabies Acute VIRAL CNS INFECTION affecting mammals, including humans. It is caused by RABIES VIRUS and usually spread by contamination with virus-laden saliva of bites inflicted by rabid animals. Important animal vectors include the dog, cat, bat, fox, raccoon, skunk, and wolf. Encephalitic Rabies,Furious Rabies,Hydrophobia,Paralytic Rabies,Lyssa,Furious Raby,Lyssas,Rabies, Encephalitic,Rabies, Furious,Raby, Furious
D011819 Rabies Vaccines Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. Rabies Human Diploid Cell Vaccine,Rabies Vaccine,Vaccine, Rabies,Vaccines, Rabies
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies

Related Publications

R S Mad'iarova, and A V Dulina, and D V Krutilina, and R G Latypova, and V M Morogova
January 1978, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
R S Mad'iarova, and A V Dulina, and D V Krutilina, and R G Latypova, and V M Morogova
November 1980, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
R S Mad'iarova, and A V Dulina, and D V Krutilina, and R G Latypova, and V M Morogova
January 1961, Bulletin of the World Health Organization,
R S Mad'iarova, and A V Dulina, and D V Krutilina, and R G Latypova, and V M Morogova
January 1977, Voprosy virusologii,
R S Mad'iarova, and A V Dulina, and D V Krutilina, and R G Latypova, and V M Morogova
September 1951, Revista. Asociacion Medica Mexicana,
R S Mad'iarova, and A V Dulina, and D V Krutilina, and R G Latypova, and V M Morogova
December 1990, Revista de saude publica,
R S Mad'iarova, and A V Dulina, and D V Krutilina, and R G Latypova, and V M Morogova
February 1981, Annals of allergy,
R S Mad'iarova, and A V Dulina, and D V Krutilina, and R G Latypova, and V M Morogova
June 1972, Boletin de la Oficina Sanitaria Panamericana. Pan American Sanitary Bureau,
R S Mad'iarova, and A V Dulina, and D V Krutilina, and R G Latypova, and V M Morogova
March 2009, JAAPA : official journal of the American Academy of Physician Assistants,
Copied contents to your clipboard!